Wave Life Sciences Ltd
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.13%.
Did WVE Beat Earnings? Q3 2025 Results
Wave Life Sciences delivered a mixed third quarter, missing on both the top and bottom lines even as its pipeline generated some of the most closely watched clinical data in its history. Revenue came in at $7.61 million, falling 27.73% short of the $10.53 million consensus, though the figure still represented a 199.1% year-over-year improvement against a prior-period quarter weighed down by a GSK collaboration accounting adjustment. EPS of -$0.32 missed the -$0.30 estimate by 8.18%, with the wider loss partly reflecting rising R&D and G&A costs tied to pipeline expansion. The standout catalyst was WVE-007, Wave's GalNAc-siRNA obesity candidate, which produced up to 85% mean Activin E reductions in the INLIGHT trial, with effects sustained through six months at the lowest dose, supporting a potential once or twice yearly dosing schedule. Cash stood at $196.22 million at quarter-end, extended into Q2 2027 following $72.10 million in post-quarter proceeds, with body weight and composition readouts from INLIGHT and WVE-006 multidose data expected through early 2026.
- Revenue improvement from positive GSK collaboration revenue recognition versus negative recognition in prior year quarter
- Interest income of $2.2 million contributed to narrowing net loss
- Net loss narrowed year-over-year despite increased R&D and G&A spending
“In the third quarter, we achieved key clinical objectives with WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency, which validate the impact of our proprietary chemistry and further solidify our growing leadership in RNAi and RNA editing. Coming out of ObesityWeek®, it is clear there is a strong need for novel non-incretin treatment approaches, and WVE-007 has the potential to disrupt the obesity treatment landscape. The successful clinical translation observed thus far, with robust and durable Activin E reductions, support WVE-007's potential to induce fat loss, preserve muscle, improve cardiometabolic health, without the class-effects of GLP-1s, and with the advantages of once or twice per year dosing.”
Wave Life Sciences CEO, on the earnings call
Forward Guidance & Outlook
Wave expects to deliver multiple clinical data updates from the INLIGHT trial for WVE-007 in obesity, including body composition and body weight data: Q4 2025 will bring three-month data from Cohort 2 (240 mg) and Cohort 1 (75 mg); Q1 2026 will bring six-month Cohort 2 data and three-month Cohort 3 (400 mg) data; Q2 2026 will bring six-month Cohort 3 data and three-month Cohort 4 (600 mg) data. For AATD, WVE-006 400 mg multidose data is expected in Q1 2026 with 600 mg single and multidose data in 2026. Wave plans to file an NDA for WVE-N531 in DMD in 2026 seeking accelerated approval. An IND submission for WVE-003's registrational Phase 2/3 study in HD is expected in H2 2025. A CTA for WVE-008 in PNPLA3 liver disease is expected in 2026. Cash runway extends into Q2 2027 following $72.1 million in post-quarter ATM proceeds and committed GSK milestones.
WVE YoY Financials
Figures from SEC filings and company reports. Not investment advice.